ofloxacin has been researched along with Body Weight in 19 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ratio of AUC from the PPK model vs MIC as the PD parameter can be applied in a dose-finding trial of antofloxacin in treatment of bacterial infections." | 9.16 | Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers. ( He, YC; Huang, JH; Li, YF; Wang, K; Yin, F; Zheng, QS, 2012) |
| " The effect of body weight and initial concentration on the rat small intestinal absorption of DL-8280 (ofloxacine) is studied using a recirculating perfusion technique and an improved HPLC method." | 7.67 | Prediction of the effect of ofloxacine on intestinal absorption: effect of the body weight and substrate concentration. ( Barrio, JP; Gómez, G; Melcón, B; Prieto, JG, 1988) |
| "Levofloxacin was recently (May 2008) approved by the U." | 6.75 | Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. ( Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW, 2010) |
| "The ratio of AUC from the PPK model vs MIC as the PD parameter can be applied in a dose-finding trial of antofloxacin in treatment of bacterial infections." | 5.16 | Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers. ( He, YC; Huang, JH; Li, YF; Wang, K; Yin, F; Zheng, QS, 2012) |
| "Levofloxacin was recently (May 2008) approved by the U." | 2.75 | Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. ( Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW, 2010) |
| "Levofloxacin is a broad-spectrum fluoroquinolone antibiotic with activity against many pathogens that cause bacterial infections in children, including penicillin-resistant pneumococci." | 2.71 | Levofloxacin pharmacokinetics in children. ( Blumer, JL; Bocchini, JA; Bradley, JS; Chien, S; Kearns, GL; Maldonado, S; Natarajan, J; Noel, GJ; Wells, TG, 2005) |
| "The aim of this study was to assess the long-term toxic effect of ofloxacin on the testes and epididymides of 72 adult male albino rats." | 1.36 | Long-term ofloxacin testicular toxicity: an experimental study. ( Abo El-Atta, HM; El-Harouny, MA; El-Shawaf, IM; Mostafa, T; Naser, ME; Zalata, AA, 2010) |
| " The terminal half-life phase of elimination from plasma was 1." | 1.31 | In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. ( Doyle, E; Edelstein, MA; Edelstein, PH; Shinzato, T, 2001) |
| "2." | 1.30 | The comparative arthropathy of fluoroquinolones in dogs. ( Hashimoto, K; Minami, T; Owen, K; Takizawa, T; Yamashita, S, 1999) |
| " No adverse effects on fertility or teratogenicity were noted at any dose." | 1.28 | Reproductive toxicity of the new quinolone antibacterial agent levofloxacin in rats and rabbits. ( Fujikawa, K; Harada, S; Ohura, K; Sasaki, T; Takayama, S; Watanabe, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, F | 1 |
| Nandy, P | 1 |
| Chien, S | 2 |
| Noel, GJ | 2 |
| Tornoe, CW | 1 |
| El-Harouny, MA | 1 |
| Zalata, AA | 1 |
| Naser, ME | 1 |
| Abo El-Atta, HM | 1 |
| El-Shawaf, IM | 1 |
| Mostafa, T | 1 |
| Luque, S | 1 |
| Grau, S | 1 |
| Valle, M | 1 |
| Colino, CI | 1 |
| Ferrer, A | 1 |
| Li, YF | 1 |
| Wang, K | 1 |
| Yin, F | 1 |
| He, YC | 1 |
| Huang, JH | 1 |
| Zheng, QS | 1 |
| Wells, TG | 1 |
| Blumer, JL | 1 |
| Kearns, GL | 1 |
| Bradley, JS | 1 |
| Bocchini, JA | 1 |
| Natarajan, J | 1 |
| Maldonado, S | 1 |
| Almeida, S | 1 |
| Filipe, A | 1 |
| Almeida, A | 1 |
| Wong, H | 1 |
| Caparrós, N | 1 |
| Tanguay, M | 1 |
| Watanabe, M | 1 |
| Yuzawa, K | 1 |
| Homma, M | 1 |
| Ohkohchi, N | 1 |
| Takizawa, T | 1 |
| Hashimoto, K | 1 |
| Minami, T | 1 |
| Yamashita, S | 1 |
| Owen, K | 1 |
| Thiel, R | 1 |
| Metzner, S | 1 |
| Gericke, C | 1 |
| Rahm, U | 1 |
| Stahlmann, R | 1 |
| Edelstein, PH | 1 |
| Shinzato, T | 1 |
| Doyle, E | 1 |
| Edelstein, MA | 1 |
| Watanabe, T | 1 |
| Fujikawa, K | 1 |
| Harada, S | 1 |
| Ohura, K | 1 |
| Sasaki, T | 1 |
| Takayama, S | 5 |
| Kato, M | 3 |
| Furuhama, K | 2 |
| Woolley, AP | 1 |
| Ashby, R | 2 |
| Fowler, JS | 2 |
| Shimada, H | 1 |
| Itoh, S | 1 |
| Hattori, C | 1 |
| Tada, S | 1 |
| Matsuura, Y | 1 |
| Kajimura, T | 1 |
| Tojo, H | 1 |
| Kudo, G | 1 |
| Yamada, M | 1 |
| Domon, S | 1 |
| Nomura, M | 1 |
| Inage, F | 1 |
| Yoshida, M | 1 |
| Akahane, K | 1 |
| West, HA | 1 |
| Virgo, DM | 1 |
| Yoneda, T | 1 |
| Nakamura, S | 1 |
| Nojima, Y | 1 |
| Nagai, A | 1 |
| Nagasawa, M | 1 |
| Nishio, Y | 1 |
| Prieto, JG | 1 |
| Barrio, JP | 1 |
| Gómez, G | 1 |
| Melcón, B | 1 |
| Grosset, JH | 1 |
1 review available for ofloxacin and Body Weight
| Article | Year |
|---|---|
Pharmacokinetics in drug screening.
Topics: Animals; Biological Availability; Body Weight; Dapsone; Drug Evaluation, Preclinical; Humans; Lepros | 1987 |
4 trials available for ofloxacin and Body Weight
| Article | Year |
|---|---|
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
Topics: Adolescent; Aging; Anthrax; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Body W | 2010 |
Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Bacteria; Bacterial Infections; Body Weight; Chromat | 2012 |
Levofloxacin pharmacokinetics in children.
Topics: Administration, Oral; Adolescent; Age Factors; Anti-Infective Agents; Area Under Curve; Biological A | 2005 |
Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Data from a randomised, 2 x 2 crossover trial in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Biological Availability; Body Weight; Chemistry, Pha | 2005 |
14 other studies available for ofloxacin and Body Weight
| Article | Year |
|---|---|
Long-term ofloxacin testicular toxicity: an experimental study.
Topics: Animals; Body Weight; Epididymis; Male; Ofloxacin; Organ Size; Rats; Spermatogenesis; Testis | 2010 |
Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient.
Topics: Anti-Bacterial Agents; Body Weight; Humans; Infusions, Intravenous; Levofloxacin; Middle Aged; Obesi | 2011 |
Establishment of an animal model with side effects induced by mycophenolate mofetil and pharmacohistological analysis of them.
Topics: Animals; Body Weight; Diarrhea; Energy Intake; Feeding Behavior; Immunosuppressive Agents; Levofloxa | 2006 |
The comparative arthropathy of fluoroquinolones in dogs.
Topics: Animals; Anti-Infective Agents; Body Weight; Ciprofloxacin; Dogs; Eating; Fluoroquinolones; Joint Di | 1999 |
Effects of fluoroquinolones on the locomotor activity in rats.
Topics: Administration, Oral; Age Factors; Animals; Anti-Infective Agents; Body Weight; Chromatography, High | 2001 |
In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Azithromycin; Body Weight; Fluoroquinolones; Gemif | 2001 |
Reproductive toxicity of the new quinolone antibacterial agent levofloxacin in rats and rabbits.
Topics: Animals; Anti-Infective Agents; Body Weight; Female; Levofloxacin; Male; Ofloxacin; Pregnancy; Prena | 1992 |
Twenty-six-week oral toxicity of the new quinolone antibacterial agent levofloxacin in rats and cynomolgus monkeys.
Topics: Animals; Anti-Infective Agents; Blood Cell Count; Body Weight; Eating; Electrocardiography; Female; | 1992 |
Mutagenicity of the new quinolone antibacterial agent levofloxacin.
Topics: Animals; Anti-Infective Agents; Body Weight; Cell Line; Cell Survival; CHO Cells; Chromosome Aberrat | 1992 |
Effect of the new quinolone antibacterial agent levofloxacin on multiple organ carcinogenesis initiated with wide-spectrum carcinogens in rats.
Topics: Animals; Anti-Infective Agents; Body Weight; Carcinogens; Drinking; Eating; Levofloxacin; Male; Neop | 1992 |
Lack of nephrotoxic effects of the new quinolone antibacterial agent levofloxacin in rabbits.
Topics: Animals; Anti-Infective Agents; Blood Urea Nitrogen; Body Weight; Cephaloridine; Creatinine; Kidney | 1992 |
Four-week sub-acute toxicity study of S-(-)-9-fluoro-2,3-dihydro-3-methyl-10- (4-methyl-1-piperazinyl)-7-oxo-7H-pyrido-[1,2,3,-de] [1,4]benzoxazine-6- carboxylic acid hemihydrate (DR-3355) in CD rats and cynomolgus monkeys.
Topics: Animals; Blood Chemical Analysis; Body Weight; Bone Marrow; Bone Marrow Cells; Eating; Female; Macac | 1991 |
[Toxicity studies on T-3262 in rat upon intravenous injection for 14 days].
Topics: Animals; Anti-Infective Agents; Body Weight; Bone Marrow; Drinking; Eating; Fluoroquinolones; Hemato | 1989 |
Prediction of the effect of ofloxacine on intestinal absorption: effect of the body weight and substrate concentration.
Topics: Animals; Anti-Infective Agents; Body Weight; Female; Intestinal Absorption; Male; Ofloxacin; Rats; R | 1988 |